Arrowhead Pharmaceuticals, Inc.
ARWRFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Arrowhead Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 16 annual periods. The latest annual period ends Sep 30, 2025. The latest insider filing shown is dated Jun 17, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Arrowhead Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-12-29 · Anzalone Christopher Richard: Larger than 154 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-12-17 · Anzalone Christopher Richard: Larger than 156 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-12-17 · Anzalone Christopher Richard: Larger than 159 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-12-15 · Anzalone Christopher Richard: Larger than 164 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-04-11 · Anzalone Christopher Richard: Larger than 161 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-04-10 · Anzalone Christopher Richard: Larger than 160 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-04-09 · Anzalone Christopher Richard: Larger than 155 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-03-13 · Anzalone Christopher Richard: Larger than 162 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-03-04 · Anzalone Christopher Richard: Larger than 165 of the 166 other insider sales of Common Stock on file. SEC filing
- 2025-03-03 · Anzalone Christopher Richard: Larger than all 166 other insider sales of Common Stock on file. SEC filing
- 2024-03-06 · Myszkowski Kenneth Allen: Larger than 158 of the 166 other insider sales of Common Stock on file. SEC filing
- 2024-01-31 · Anzalone Christopher Richard: Larger than 157 of the 166 other insider sales of Common Stock on file. SEC filing
- 2023-10-25 · Anzalone Christopher Richard: Larger than 150 of the 166 other insider sales of Common Stock on file. SEC filing
- 2023-09-18 · Anzalone Christopher Richard: Larger than 152 of the 166 other insider sales of Common Stock on file. SEC filing
- 2023-09-18 · Anzalone Christopher Richard: Larger than 153 of the 166 other insider sales of Common Stock on file. SEC filing
- 2023-05-04 · Anzalone Christopher Richard: Larger than 151 of the 166 other insider sales of Common Stock on file. SEC filing
- 2023-05-03 · Anzalone Christopher Richard: Larger than 163 of the 166 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-12 | Lu Hongbo · Director | Common Stock | S — Open market or private sale | −2,970 | 76.88 | SEC filing |
| 2026-04-23 | Hamilton James C · Chief Medical Officer | Common Stock | S — Open market or private sale | −10,000 | 75.00 | SEC filing |
| 2026-04-22 | Apel Daniel Joseph · Chief Financial Officer | Common Stock | S — Open market or private sale | −8,730 | 71.92 | SEC filing |
| 2026-04-22 | Apel Daniel Joseph · Chief Financial Officer | Common Stock | S — Open market or private sale | −1,157 | 70.45 | SEC filing |
| 2026-04-22 | Apel Daniel Joseph · Chief Financial Officer | Common Stock | S — Open market or private sale | −3,208 | 70.11 | SEC filing |
| 2026-03-05 | Hamilton James C · Chief Medical Officer | Common Stock | S — Open market or private sale | −10,000 | 64.19 | SEC filing |
| 2026-01-05 | Hamilton James C · Chief Medical Officer | Common Stock | S — Open market or private sale | −1,200 | 64.49 | SEC filing |
| 2026-01-05 | O'Brien Patrick · COO | Common Stock | S — Open market or private sale | −6,164 | 62.23 | SEC filing |
Showing 8 of 18 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-15 | Cohen Matthew Gregory · Director | Common Stock | A — Grant, award, or other acquisition | +11,882 | SEC filing |
| 2026-01-06 | O'Brien Patrick · COO | Common Stock | G — Bona fide gift | −440 | SEC filing |
| 2026-01-06 | O'Brien Patrick · COO | Common Stock | G — Bona fide gift | −540 | SEC filing |
| 2026-01-06 | O'Brien Patrick · COO | Common Stock | A — Grant, award, or other acquisition | +75,000 | SEC filing |
| 2026-01-06 | Apel Daniel Joseph · Chief Financial Officer | Common Stock | A — Grant, award, or other acquisition | +75,000 | SEC filing |
| 2026-01-06 | Hamilton James C · Chief Medical Officer | Common Stock | A — Grant, award, or other acquisition | +75,000 | SEC filing |
| 2025-12-31 | O'Brien Patrick · COO | Common Stock | G — Bona fide gift | −560 | SEC filing |
| 2025-12-29 | Anzalone Christopher Richard · Chief Executive Officer | Common Stock | M — Exercise or conversion of derivative security | +16,545 | SEC filing |
Showing 8 of 24 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-01-10 | Vakiener Victoria · Director | Common Stock | D — Disposition to the issuer | −1,764 | SEC filing |
Showing 1 of 1 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.